{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:25:06Z","timestamp":1793273106810,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euf.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:26:47Z","timestamp":1777289207000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1004-1459","authenticated-orcid":false,"given":"Rouvier","family":"Al-Monajjed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Krilaviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.04.008_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2025.12.002","article-title":"Risk-adapted prostate cancer screening achieves mammography-like benefits: evidence and implications for Europe","volume":"89","author":"Carlsson","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.04.008_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2026.04.008_b0015","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.04.008_b0020","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2026.04.008_b0025","unstructured":"Richtlinien des Bundesausschusses der \u00c4rzte und Krankenkassen \u00fcber die Fr\u00fcherkennung von Krebserkrankungen (Krebsfr\u00fcherkennungs-Richtlinien) vom 28. April 1971. Dtsch \u00c4rztebl 1971;25:1914\u20136."},{"key":"10.1016\/j.euf.2026.04.008_b0030","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","article-title":"Digital rectal examination is not a useful screening test for prostate cancer","volume":"6","author":"Krilaviciute","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.04.008_b0035","unstructured":"Oncology guidelines program (German cancer society, German cancer aid, Association of the Scientific Medical Societies in Germany). S3 guideline prostate cancer. version 8.0. AWMF Register No. 043-022OL; 2025, https:\/\/www.leitlinienprogramm-onkologie.de."},{"key":"10.1016\/j.euf.2026.04.008_b0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE trial","volume":"86","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.04.008_b0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2026.04.008_b0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","article-title":"Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial","volume":"85","author":"Boschheidgen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.04.008_b0055","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.04.008_b0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2025.05.020","article-title":"Prostate cancer detection in younger men: A comparative analysis of systematic and magnetic resonance imaging-targeted biopsy in the PROBASE trial","volume":"88","author":"Al-Monajjed","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.04.008_b0065","doi-asserted-by":"crossref","unstructured":"Al-Monajjed R, Boschheidgen M, Lakes J, et al. Value of additional systematic cores during magnetic resonance imaging-guided targeted biopsy in prostate cancer screening for young men: results from the PROBASE trial. Eur Urol Oncol In press. https:\/\/doi.org\/10.1016\/j.euo.2025.10.014.","DOI":"10.1016\/j.euo.2025.10.014"},{"key":"10.1016\/j.euf.2026.04.008_b0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.euo.2024.10.002","article-title":"Diagnostic effects of omitting systematic biopsies in prostate cancer screening","volume":"8","author":"Chandra Engel","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:26:53Z","timestamp":1777289213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S2405456926000581"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.04.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}